Фармсинтез LIFE

Quarterly report 2024-Q4
added 08-10-2026

Фармсинтез Financial Ratios 2024-2007 | LIFE

Brief overview of Фармсинтез's market valuation

The comparison uses the five latest available annual observations between 2008 and 2018.

The latest available valuation ratios are P/E 27.1x (median 367.11x), EV/EBITDA 196.63x (median 249.53x), P/S 6x (median 4.29x). The combined ratio level is close to the company's five-year norm at a +9.3% deviation. No clear premium or discount is visible.

At the current P/E, inverse earnings yield is 3.7%, a useful bridge between price and business earnings.

Returns on assets and capital are represented by ROE -57.8%, ROA -17.9%, ROCE -30.2%. The business is not generating positive returns on invested resources. Valuation should be read cautiously until earnings recover.

Current and quick ratios are 0.17x and 0.13x. The balance sheet has a limited reserve.

Debt ratios point to higher risk: debt/equity 9.19x, interest coverage -7.24x.

The cash conversion cycle lengthened from -360.3 days to -166.9 days, or 193.4 days. More cash is tied up in operations.

Overall assessment

Фармсинтез trades near its familiar ratio range. A new earnings or profitability trend is needed to change the view.

Annual Financial Ratios Фармсинтез

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Price Earnings Ratio, P/E	-	-8	-6.09	-2.42	-3.93	-0.69	27.1	-1.31	-2.79	-4.62	-8.85	-12.45	-15.04	435.18	367.11	213.28	1410.81	177.55
Price Sales Ratio, P/S	-	6	3.33	3.85	5.55	4.29	5.75	4.58	3.79	4.95	4.8	7.48	3.08	14.79	25.42	13.11	16.64	17.36
Price To Book Ratio, P/B	-	27	10.43	4.89	2.03	0.3	0.33	1.88	0.54	0.77	0.78	1.06	1.18	7.37	24.18	11.08	11.27	11.35
Price Earnings To Growth Ratio, PEG	-	-	0.09	-0.07	0.06	0.0	-0.26	-0.02	-0.02	-0.07	-2.02	-0.16	0.01	-16.4	-8.65	0.39	-16.06	-
Operating Cash Flow Per Share	-	-1.06	-0.01	-0.21	-0.77	-0.32	-0.05	-0.5	-3.81	-1.34	-5.89	-3.27	-1.65	0.18	-	-	-	-
Free Cash Flow Per Share	-	-1	-0.02	-0.21	-0.81	-0.37	-0.12	-0.59	-4.03	-1.44	-6.46	-4.43	-2.67	-0.1	-0.05	-0.04	-0.03	-
Cash Per Share	-	0.06	0.03	0.05	0.03	0.25	0.05	1.37	3.02	2.03	1.25	5.16	1.08	1.15	1.55	0.18	0.03	0.05
Current Ratio	-	-	0.17	0.21	0.45	0.27	0.38	0.97	1.8	1.92	5.32	2.55	2.01	3.67	1.13	1.49	1.37	1.21
Quick Ratio	-	-	0.13	0.17	0.39	0.16	0.18	0.79	1.62	1.61	4.62	2.37	1.67	3.3	1.0	0.85	0.78	0.7
Cash Ratio	-	-	0.01	0.02	0.01	0.04	0.0	0.29	0.39	0.01	0.5	1.16	0.37	0.02	0.02	0.21	0.03	0.06
Days Of Sales Outstanding, DSO	-	-	-	-	-	-	-	223.54	326.27	466.14	-	232.19	208.62	-	-	-	-	-
Days Of Inventory Outstanding, DIO	-	-	51.23	47.63	119.91	213.33	393.03	181.58	230.38	488.98	343.85	185.71	159.18	80.42	165.58	157.1	247.77	219.47
Days Of Payables Outstanding, DPO	-	-	218.15	185.98	306.44	335.64	753.34	391.6	6610.55	389.91	284.97	124.61	323.0	-	138.24	173.17	307.87	384.67
Operating Cycle	-	-	51.23	47.63	119.91	213.33	393.03	405.12	556.64	955.12	343.85	417.9	367.79	80.42	165.58	157.1	247.77	219.47
Cash Conversion Cycle	-	-	-166.92	-138.34	-186.53	-122.32	-360.31	13.51	-6053.91	565.21	58.89	293.29	44.8	80.42	27.35	-16.07	-60.09	-165.2
Gross Profit Margin	-	-	0.21	0.37	0.43	0.1	0.11	0.43	0.59	0.49	0.56	0.37	0.45	0.28	0.38	0.32	0.44	0.46
Operating Profit Margin	-	-0.65	-0.44	-0.39	-0.11	-6.94	0.24	-3.98	-0.93	-1.81	-0.55	-0.73	-0.68	0.01	0.15	0.07	0.12	0.19
Pretax Profit Margin	-	-0.73	-0.55	-1.67	-1.42	-6.97	0.01	-3.93	-1.43	-1.2	-0.53	-0.63	-0.23	0.07	0.1	0.03	0.03	0.14
Net Profit Margin	-	-0.73	-0.55	-1.59	-1.41	-6.22	0.21	-3.49	-1.36	-1.07	-0.54	-0.6	-0.2	0.03	0.07	0.06	0.01	0.1
Effective Tax Rate	-	-	0.01	0.05	0.0	-0.11	-32.04	0.03	0.04	0.11	-0.03	0.04	0.12	0.5	0.29	-1.26	0.62	0.32
Return On Assets, ROA	-	-0.18	-0.16	-0.49	-0.26	-0.31	0.01	-0.75	-0.15	-0.12	-0.08	-0.07	-0.06	0.01	0.02	0.04	0.01	0.04
Return On Equity, ROE	-	-0.58	-1.71	-2.02	-0.52	-0.43	0.01	-1.43	-0.2	-0.17	-0.09	-0.09	-0.08	0.02	0.07	0.05	0.01	0.06
Return On Capital Employed, ROCE	-	-0.3	-1.03	-0.39	-0.04	-0.46	0.01	-1.29	-0.12	-0.28	-0.09	-0.1	-0.26	0.0	0.14	0.06	0.08	0.12
Net Income Per Ebt	-	1.0	0.99	0.95	1.0	0.89	33.04	0.89	0.95	0.89	1.03	0.96	0.88	0.5	0.71	2.26	0.38	0.68
Ebt Per Ebit	-	1.13	1.25	4.34	12.73	1.0	0.03	0.99	1.53	0.66	0.95	0.85	0.34	9.33	0.64	0.38	0.27	0.76
Ebit Per Revenue	-	-0.65	-0.44	-0.39	-0.11	-6.94	0.24	-3.98	-0.93	-1.81	-0.55	-0.73	-0.68	0.01	0.15	0.07	0.12	0.19
Debt Ratio	-	0.95	0.56	0.5	0.3	0.03	0.0	0.07	0.04	0.1	0.01	0.16	0.05	0.01	0.0	0.06	0.06	0.02
Debt Equity Ratio	-	9.19	6.16	2.05	0.61	0.04	0.0	0.13	0.05	0.14	0.01	0.2	0.06	0.01	0.0	0.08	0.09	0.03
Long Term Debt To Capitalization	-	0.9	0.12	0.2	0.01	0.03	-	0.03	-	-	-	-	-	-	-	-	-	-
Total Debt To Capitalization	-	0.9	0.86	0.67	0.38	0.04	0.0	0.12	0.05	0.12	0.01	0.17	0.06	0.01	0.0	0.07	0.09	0.03
Interest Coverage	-	-7.24	-4.05	-4.65	-1.4	-	11.49	-634.17	-194.6	-279.15	-98.25	-96.71	-37.61	1	33.06	5.4	12.82	232.68
Cash Flow To Debt Ratio	-	-0.63	-0.0	-0.09	-0.37	-0.59	-0.67	-0.59	-2.58	-0.69	-24.39	-1.02	-2.75	8.93	-	-	-	-
Company Equity Multiplier	-	19.25	11.05	4.13	2.02	1.4	1.33	1.92	1.33	1.35	1.1	1.26	1.27	1.23	3.1	1.39	1.45	1.43
Receivables Turnover	-	-	-	-	-	-	-	1.63	1.12	0.78	-	1.57	1.75	-	-	-	-	-
Payables Turnover	-	-	1.67	1.96	1.19	1.09	0.48	0.93	0.06	0.94	1.28	2.93	1.13	-	2.64	2.11	1.19	0.95
Inventory Turn Over	-	-	7.12	7.66	3.04	1.71	0.93	2.01	1.58	0.75	1.06	1.97	2.29	4.54	2.2	2.32	1.47	1.66
Fixed Asset Turnover	-	-	1.1	1.34	1.06	0.93	0.85	1.76	1.64	0.76	0.81	0.6	0.79	8.58	1.43	1.17	0.87	0.77
Asset Turnover	-	0.25	0.28	0.31	0.18	0.05	0.04	0.21	0.11	0.12	0.15	0.11	0.3	0.41	0.31	0.61	0.47	0.46
Operating Cash Flow Sales Ratio	-	-1.22	-0.01	-0.14	-0.63	-0.33	-0.05	-0.19	-0.87	-0.61	-2.23	-1.44	-0.44	0.13	-	-	-	-
Free Cash Flow Operating Cash Flow Ratio	-	1.23	2.04	1.0	1.04	1.15	2.25	1.18	1.06	1.07	1.1	1.35	1.62	-0.54	-	-	-	-
Cash Flow Coverage Ratios	-	-0.63	-0.0	-0.09	-0.37	-0.59	-0.67	-0.59	-2.58	-0.69	-24.39	-1.02	-2.75	8.93	-	-	-	-
Short Term Coverage Ratios	-	-	-0.0	-0.1	-0.38	-0.32	-0.67	-0.78	-2.58	-0.71	-35.45	-1.04	-2.96	8.93	-	-	-	-
Capital Expenditure Coverage Ratio	-	-4.39	-0.97	-224.71	-24.04	-6.66	-0.8	-5.67	-17.2	-13.95	-10.36	-2.82	-1.61	0.65	-	-	-	-
Dividend Paid And Capex Coverage Ratio	-	-4.39	-0.97	-224.71	-24.04	-6.66	-0.8	-5.67	-17.2	-13.95	-10.36	-2.82	-1.61	0.65	-	-	-	-
Price To Free Cash Flows Ratio, P/FCF	-	-3.94	-185.11	-26.82	-8.5	-11.24	-46.49	-20.49	-4.1	-7.5	-1.97	-3.84	-4.35	-212.02	-503.78	-599.39	-791.95	-
Price To Operating Cash Flows Ratio, P/OCF	-	-4.84	-376.79	-26.93	-8.86	-12.93	-104.6	-24.1	-4.34	-8.04	-2.16	-5.19	-7.05	113.77	-	-	-	-
Price Cash Flow Ratio, P/CF	-	-4.84	-376.79	-26.93	-8.86	-12.93	-104.6	-24.1	-4.34	-8.04	-2.16	-5.19	-7.05	113.77	-	-	-	-
Enterprise Value Multiple, EV	-	-	-14.29	-3.68	-13.43	-7.03	-7.69	-3.2	-3.84	-5.29	-10.82	-14.09	-26.44	196.63	249.53	323.42	416.32	120.47
Price Fair Value, P/FV	-	27	10.43	4.89	2.03	0.3	0.33	1.88	0.54	0.77	0.78	1.06	1.18	7.37	24.18	11.08	11.27	11.35

All numbers in RUB currency

Quarterly Financial Ratios Фармсинтез

	2023-Q2	2022-Q4	2022-Q2	2021-Q4	2021-Q2	2020-Q4	2020-Q2	2019-Q4	2019-Q2	2018-Q4	2018-Q2	2017-Q4	2017-Q2	2016-Q4	2016-Q2	2015-Q4	2015-Q2	2014-Q4	2014-Q2	2013-Q4	2013-Q2	2012-Q4	2011-Q4	2011-Q2	2010-Q4	2010-Q2	2009-Q4	2009-Q2	2008-Q4	2008-Q2
Price Earnings Ratio, P/E	-3.76	-6.11	-4.52	-0.948	-1.85	-1.24	-4.56	-0.17	-10.3	-13.1	-1.43	-0.741	-0.612	-0.543	1.19	-5.72	-1.69	-4.43	-4.82	3.38	-2.94	-7.52	218	250	184	189	107	107	88.8	705
Price Sales Ratio, P/S	3.32	3.33	5.86	7.8	8.41	8.99	13.8	12.8	8.46	6.71	21.1	7.92	10.8	5.35	12.6	13.2	7.75	9.6	10.5	8.08	38.1	6.16	29.6	34	50.8	52.5	26.2	26.2	34.7	33.3
Price To Book Ratio, P/B	4.63	-4.61	3.54	4.89	2.5	2.03	1.41	0.883	0.368	0.473	1.63	1.71	1.44	0.545	0.952	0.771	0.961	0.783	1.07	1.22	1.2	1.18	7.37	12.6	24.2	25.8	11.1	11.2	-	11.3
Price Earnings To Growth Ratio, PEG	-0.279	-0.019	0.053	-0.012	0.047	-0.004	0.048	-0.0	-0.483	0.143	0.021	0.039	0.018	0.002	-0.001	0.077	-0.01	-	0.031	-0.019	-0.009	-	-	-9.44	-	-4.47	-	0.195	-	-8.03
Operating Cash Flow Per Share	-0.001	0.0	-0.0	-0.118	-0.09	-0.469	-0.308	-0.082	-0.144	-0.0	-0.0	0.0	-0.0	-0.003	0.0	-0.001	-0.0	-0.003	-0.003	-1.43	-1.91	-1.25	0.089	0.089	-	-	-	-	-	-
Free Cash Flow Per Share	-0.001	0.0	-0.0	-0.119	-0.091	-0.489	-0.32	-0.132	-0.144	-0.0	-0.0	0.0	-0.0	-0.003	0.0	-0.001	-0.0	-0.003	-0.003	-1.94	-2.58	-1.69	-0.048	-0.048	-0.023	-0.023	-0.02	-0.02	-0.008	-0.015
Cash Per Share	0.848	0.145	0.003	0.045	0.04	0.035	0.06	0.231	0.043	0.016	0.837	1.51	0.297	3.02	0.818	2.27	1.49	1.25	2.99	4.52	9.62	1.08	1.15	1.35	1.55	0.812	0.18	0.106	-	0.04
Current Ratio	0.542	0.169	0.25	0.208	0.303	0.454	0.516	0.505	0.266	0.578	0.695	0.974	1.16	1.8	1.16	1.92	3.74	5.32	7.35	2.55	2.9	2.01	3.67	1.7	1.13	1.18	1.49	1.43	-	1.29
Quick Ratio	0.46	0.133	0.209	0.171	0.233	0.386	0.423	0.421	0.112	0.385	0.536	0.793	0.982	1.62	0.982	1.61	3.02	4.62	6.54	2.37	2.72	1.67	3.3	1.52	0.999	0.978	0.854	0.817	-	0.744
Cash Ratio	0.248	0.008	0.003	0.015	0.011	0.01	0.018	0.073	0.0	0.005	0.169	0.286	0.006	0.386	0.006	0.01	0.041	0.501	2.5	1.16	1.89	0.372	0.017	0.019	0.019	0.047	0.211	0.116	-	0.042
Days Of Sales Outstanding, DSO	112	37.8	83.5	-	95.6	114	251	-	69.5	87.1	267	109	-	93.9	65	107	87.6	-	-	-	-	-	-	-	-	-	-	-	-	-
Days Of Inventory Outstanding, DIO	64.4	25	23.4	19.6	60	47.1	104	47.3	188	139	131	154	51.1	971	67.1	131	66.3	170	137	29.9	227	78.5	39.7	43.3	81.7	76.1	77.5	78.4	-	112
Days Of Payables Outstanding, DPO	227	106	238	76.6	176	421	796	148	850	205	317	213	55.6	1.58 K	73.1	143	47.3	141	123	22.9	1.04 K	159	-	19.6	68.2	73	85.4	91.9	-	164
Operating Cycle	177	62.7	107	19.6	156	161	355	47.3	257	226	399	263	51.1	1.06 K	132	239	154	170	137	29.9	227	78.5	39.7	43.3	81.7	76.1	77.5	78.4	-	112
Cash Conversion Cycle	-50.2	-43.6	-131	-57	-19.9	-260	-441	-100	-592	21.2	81.4	50.6	-4.51	-514	59.1	95.4	107	29	13.5	6.99	-814	-80.8	39.7	23.7	13.5	3.13	-7.93	-13.6	-	-52.8
Gross Profit Margin	0.31	0.119	0.29	0.233	0.498	0.42	0.447	-0.559	0.414	0.486	-0.323	0.684	0.045	0.966	-0.293	-0.241	-0.189	0.563	0.563	0.086	0.299	0.447	0.284	0.284	0.384	0.384	0.323	0.323	0.458	0.443
Operating Profit Margin	-0.723	-0.393	-0.315	-0.531	-0.96	-0.355	-0.433	-20.2	-0.578	0.244	-2.37	-1.44	-1.36	-2.8	3.77	-2.16	-1.14	-0.551	-0.551	-0.525	-0.63	-0.683	0.007	0.007	0.152	0.152	0.072	0.072	0.187	0.116
Pretax Profit Margin	-0.822	-0.956	-0.165	-2.1	-1.18	-1.53	-0.843	-20.3	-0.593	-0.17	-4.89	-3.47	-4.44	-2.52	2.53	-0.96	-1.13	-0.526	-0.526	0.592	-3.28	-0.233	0.068	0.068	0.098	0.098	0.027	0.027	0.143	0.031
Net Profit Margin	-0.949	-0.816	-0.324	-2.06	-1.14	-1.82	-0.756	-18.8	-0.206	-0.128	-3.71	-2.67	-4.39	-2.46	2.66	-0.577	-1.15	-0.542	-0.542	0.598	-3.23	-0.205	0.034	0.034	0.069	0.069	0.061	0.061	0.098	0.012
Effective Tax Rate	-0.154	-0.147	-0.665	0.038	0.072	-0.059	0.192	-0.074	-0.652	-0.246	-0.241	-0.041	-0.012	-0.011	0.049	-0.399	-0.015	-0.03	-0.03	0.011	-0.014	0.123	0.5	0.5	0.295	0.295	-1.26	-1.26	0.318	0.622
Return On Assets, ROA	-0.177	-0.154	-0.05	-0.312	-0.136	-0.203	-0.043	-0.73	-0.007	-0.007	-0.124	-0.301	-0.417	-0.188	0.142	-0.025	-0.123	-0.04	-0.051	0.072	-0.077	-0.031	0.007	0.007	0.011	0.015	0.019	0.018	-	0.003
Return On Equity, ROE	-0.475	-2	-0.196	-1.29	-0.338	-0.411	-0.077	-1.3	-0.009	-0.009	-0.286	-0.578	-0.589	-0.251	0.201	-0.034	-0.142	-0.044	-0.055	0.09	-0.102	-0.039	0.008	0.013	0.033	0.034	0.026	0.026	-	0.004
Return On Capital Employed, ROCE	-0.194	-1.17	-0.158	-0.266	-0.267	-0.079	-0.041	-1.27	-0.025	0.017	-0.132	-0.245	-0.183	-0.254	0.285	-0.126	-0.14	-0.045	-0.056	-0.079	-0.02	-0.13	0.002	0.003	0.072	0.074	0.03	0.03	-	0.039
Net Income Per Ebt	1.15	0.853	1.96	0.979	0.964	1.19	0.897	0.926	0.348	0.754	0.759	0.771	0.988	0.979	1.05	0.601	1.01	1.03	1.03	1.01	0.986	0.877	0.5	0.5	0.705	0.705	2.26	2.26	0.682	0.378
Ebt Per Ebit	1.14	2.43	0.526	3.95	1.23	4.31	1.95	1	1.02	-0.697	2.06	2.41	3.26	0.899	0.671	0.445	0.992	0.954	0.954	-1.13	5.21	0.342	9.33	9.33	0.645	0.645	0.38	0.38	0.765	0.268
Ebit Per Revenue	-0.723	-0.393	-0.315	-0.531	-0.96	-0.355	-0.433	-20.2	-0.578	0.244	-2.37	-1.44	-1.36	-2.8	3.77	-2.16	-1.14	-0.551	-0.551	-0.525	-0.63	-0.683	0.007	0.007	0.152	0.152	0.072	0.072	0.187	0.116
Debt Ratio	0.444	0.557	0.446	0.497	0.232	0.196	0.111	0.105	0.006	0.073	0.095	0.069	0.164	0.037	0.164	0.103	0.009	0.014	0.017	0.161	0.039	0.048	0.006	0.003	0.0	0.017	0.058	0.061	-	0.043
Debt Equity Ratio	1.2	6.16	1.75	2.05	0.578	0.396	0.198	0.187	0.008	0.096	0.22	0.132	0.232	0.049	0.232	0.139	0.011	0.015	0.019	0.202	0.051	0.061	0.007	0.005	0.0	0.039	0.08	0.087	-	0.062
Long Term Debt To Capitalization	0.032	0.12	0.141	0.201	0.063	0.013	0.07	0.093	0.012	0.017	0.07	0.027	-	-	-	-	0.002	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Debt To Capitalization	0.545	0.86	0.636	0.672	0.366	0.284	0.165	0.157	0.008	0.088	0.18	0.117	0.188	0.046	0.188	0.122	0.011	0.015	0.019	0.168	0.049	0.057	0.007	0.005	0.0	0.037	0.074	0.08	-	0.059
Interest Coverage	-	-	-3.45	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-98.3	-98.3	-	-	-37.6	1	1	33.1	33.1	5.4	5.4	233	12.8
Cash Flow To Debt Ratio	-0.0	0.0	-0.0	-0.05	-0.063	-0.351	-0.334	-0.094	-1.25	-0.0	-0.0	0.0	-0.0	-0.002	0.0	-0.001	-0.002	-0.013	-0.011	-0.508	-2.33	-2.09	4.46	8.85	-	-	-	-	-	-
Company Equity Multiplier	2.7	11	3.92	4.13	2.49	2.02	1.78	1.78	1.36	1.31	2.31	1.92	1.41	1.33	1.41	1.35	1.15	1.1	1.09	1.26	1.32	1.27	1.23	1.71	3.1	2.27	1.39	1.42	-	1.44
Receivables Turnover	0.803	2.38	1.08	-	0.941	0.788	0.359	-	1.29	1.03	0.337	0.827	-	0.958	1.38	0.837	1.03	-	-	-	-	-	-	-	-	-	-	-	-	-
Payables Turnover	0.397	0.846	0.378	1.17	0.513	0.214	0.113	0.609	0.106	0.439	0.284	0.423	1.62	0.057	1.23	0.627	1.9	0.64	0.731	3.93	0.086	0.565	-	4.59	1.32	1.23	1.05	0.979	-	0.548
Inventory Turn Over	1.4	3.6	3.85	4.59	1.5	1.91	0.863	1.9	0.48	0.646	0.685	0.583	1.76	0.093	1.34	0.685	1.36	0.531	0.659	3.01	0.396	1.15	2.27	2.08	1.1	1.18	1.16	1.15	-	0.807
Fixed Asset Turnover	0.506	0.498	0.661	0.663	0.655	0.652	0.393	0.254	0.61	0.647	0.261	0.923	0.832	1.16	0.468	0.286	0.55	0.406	0.419	0.635	0.127	0.395	4.29	1.72	0.717	0.712	0.586	0.568	-	0.419
Asset Turnover	0.101	0.128	0.154	0.152	0.119	0.112	0.057	0.039	0.032	0.054	0.033	0.113	0.095	0.076	0.053	0.043	0.107	0.074	0.094	0.12	0.024	0.151	0.203	0.215	0.153	0.216	0.304	0.3	-	0.236
Operating Cash Flow Sales Ratio	-0.002	0.0	-0.0	-0.164	-0.123	-0.615	-0.645	-0.254	-0.228	-0.0	-0.0	0.0	-0.0	-0.001	0.0	-0.001	-0.0	-0.002	-0.002	-0.68	-3.77	-0.663	0.13	0.13	-	-	-	-	-	-
Free Cash Flow Operating Cash Flow Ratio	1.1	0.917	1.08	1.01	1	1.04	1.04	1.61	1	0.94	1.67	0.271	1.02	1.02	0.96	1.08	1.04	1.09	1.1	1.35	1.35	1.35	-0.537	-0.537	-	-	-	-	-	-
Cash Flow Coverage Ratios	-0.0	0.0	-0.0	-0.05	-0.063	-0.351	-0.334	-0.094	-1.25	-0.0	-0.0	0.0	-0.0	-0.002	0.0	-0.001	-0.002	-0.013	-0.011	-0.508	-2.33	-2.09	4.46	8.85	-	-	-	-	-	-
Short Term Coverage Ratios	-0.0	0.0	-0.0	-0.057	-0.071	-0.363	-0.54	-0.08	-1.25	-0.0	-0.0	0.0	-0.0	-0.001	0.0	-0.001	-0.003	-0.019	-0.014	-0.519	-2.53	-2.25	4.46	8.85	-	-	-	-	-	-
Capital Expenditure Coverage Ratio	-9.86	12	-12.5	-168	-400	-23.2	-25.5	-1.65	-	-16.8	-1.5	1.37	-49.5	-46.1	25.1	-12.2	-27.5	-10.8	-9.91	-2.82	-2.82	-2.82	0.651	0.651	-	-	-	-	-	-
Dividend Paid And Capex Coverage Ratio	-9.86	12	-12.5	-168	-400	-23.2	-25.5	-1.65	-	-16.8	-1.5	1.37	-49.5	-46.1	25.1	-12.2	-27.5	-10.8	-9.91	-2.82	-2.82	-2.82	0.651	0.651	-	-	-	-	-	-
Price To Free Cash Flows Ratio, P/FCF	-6 K	68.7 K	-49.1 K	-47.3	-68.4	-14	-20.6	-31.3	-37	-22.7 K	-36.8 K	1.25 M	-24.7 K	-5.65 K	62.2 K	-9.59 K	-40.7 K	-3.66 K	-4.62 K	-8.77	-7.45	-6.86	-424	-488	-1.01 K	-1.04 K	-1.2 K	-1.2 K	-3.17 K	-1.58 K
Price To Operating Cash Flows Ratio, P/OCF	-6.61 K	63 K	-53 K	-47.6	-68.6	-14.6	-21.4	-50.3	-37	-21.4 K	-61.5 K	338 K	-25.2 K	-5.78 K	59.8 K	-10.4 K	-42.2 K	-4 K	-5.09 K	-11.9	-10.1	-9.28	228	262	-	-	-	-	-	-
Price Cash Flow Ratio, P/CF	-6.61 K	63 K	-53 K	-47.6	-68.6	-14.6	-21.4	-50.3	-37	-21.4 K	-61.5 K	338 K	-25.2 K	-5.78 K	59.8 K	-10.4 K	-42.2 K	-4 K	-5.09 K	-11.9	-10.1	-9.28	228	262	-	-	-	-	-	-
Enterprise Value Multiple, EV	-6.19	-14.5	-487	-5.39	-10	-8	-24.6	-8.72	-53	2.51	-2.27	-1.12	-4.9	-0.902	-11.3	-7.63	-7.26	-21.6	-20.2	-16.8	-42.6	-52.9	393	452	499	515	647	649	-	830
Price Fair Value, P/FV	3.59	10.2	3.54	4.89	2.5	2.03	1.41	0.883	0.368	0.473	1.63	1.71	1.44	0.545	0.952	0.771	0.961	0.783	1.07	1.22	1.2	1.18	7.37	12.6	24.2	25.8	11.1	11.2	-	11.3

All numbers in RUB currency

Multiples are an important financial analysis tool for the company Фармсинтез, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios

Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer	Price	% 24h	Market Cap	Country
Институт стволовых клеток человека ISKJ	-	-	-	Russia
ММЦБ GEMA	-	-	-	Russia
Lyra Therapeutics LYRA	-	-	$ 24.9 M	USA
Завод ДИОД DIOD	-	-	-	Russia
ОЗОН Фармацевтика OZPH	-	-	-	Russia
Промомед PRMD	-	-	-	Russia
Brickell Biotech BBI	-	-5.38 %	$ 6.06 M	USA
Applied Therapeutics APLT	-	-	$ 8.42 M	USA
ESSA Pharma EPIX	-	-	$ 8.86 M	Canada
Generation Bio Co. GBIO	-	-	$ 344 M	USA
Clearside Biomedical CLSD	-	-	$ 25.3 M	USA
Merus N.V. MRUS	-	-	$ 5.78 B	Niderland
RAPT Therapeutics RAPT	-	-	$ 2.36 B	USA
Exicure XCUR	$ 1.01	1.3 %	$ 6.36 M	USA
Cellectis S.A. CLLS	$ 0.97	-2.17 %	$ 97.3 M	France
AbCellera Biologics ABCL	$ 12.24	4.53 %	$ 3.66 B	Canada
Arrowhead Pharmaceuticals ARWR	$ 58.84	-0.14 %	$ 7.87 B	USA
BioMarin Pharmaceutical BMRN	$ 55.21	-2.18 %	$ 10.6 B	USA
Celldex Therapeutics CLDX	$ 29.37	-3.04 %	$ 1.95 B	USA
CollPlant Biotechnologies Ltd. CLGN	$ 3.76	-3.22 %	$ 45.9 M	Israel
Jaguar Health JAGX	$ 2.28	-13.31 %	$ 5.32 M	USA
Protalix BioTherapeutics PLX	$ 2.57	-2.65 %	$ 202 M	Israel
uniQure N.V. QURE	$ 22.69	-0.11 %	$ 1.3 B	Niderland
Stoke Therapeutics STOK	$ 25.68	-3.49 %	$ 1.52 B	USA
Xencor XNCR	$ 25.16	0.88 %	$ 1.87 B	USA
Annexon ANNX	$ 3.86	0.78 %	$ 599 M	USA
Can-Fite BioPharma Ltd. CANF	$ 1.89	-0.02 %	$ 3.11 M	Israel
Incyte Corporation INCY	$ 113.44	-2.72 %	$ 22.1 B	USA
Mesoblast Limited MESO	$ 12.83	3.38 %	$ 15.5 B	Australia
MeiraGTx Holdings plc MGTX	$ 9.86	-1.1 %	$ 793 M	USA
Vertex Pharmaceuticals Incorporated VRTX	$ 524.52	1.92 %	$ 134 B	USA
AbbVie ABBV	$ 284.8	-1.45 %	$ 504 B	USA
Arcutis Biotherapeutics ARQT	$ 31.87	-2.89 %	$ 4.05 B	USA
Altimmune ALT	$ 2.23	-3.04 %	$ 196 M	USA
Arbutus Biopharma Corporation ABUS	$ 4.18	-3.46 %	$ 801 M	Canada
Axon Enterprise AXON	$ 402.6	2.54 %	$ 31.4 B	USA
Oncternal Therapeutics ONCT	-	-24.12 %	$ 1.56 M	USA
Black Diamond Therapeutics BDTX	$ 2.08	0.48 %	$ 118 M	USA
Burford Capital Limited BUR	$ 3.05	-0.65 %	$ 668 M	Britain
Catalyst Biosciences CBIO	$ 13.17	0.77 %	$ 1.18 B	USA
Seagen SGEN	-	-	$ 42.2 B	USA
Codexis CDXS	$ 1.29	4.88 %	$ 112 M	USA
Cullinan Management CGEM	$ 14.89	0.4 %	$ 897 M	USA
Compugen Ltd. CGEN	$ 2.12	-0.93 %	$ 198 M	Israel
Alpine Immune Sciences ALPN	-	-	$ 2.17 B	USA
Applied Genetic Technologies Corporation AGTC	-	-	$ 26.5 M	USA
Aclaris Therapeutics ACRS	$ 3.81	1.06 %	$ 467 M	USA
Cellectar Biosciences CLRB	$ 1.28	4.07 %	$ 3.34 M	USA
Cocrystal Pharma COCP	$ 0.96	1.81 %	$ 10.8 M	USA

Фармсинтез Financial Ratios 2024-2007 | LIFE

Brief overview of Фармсинтез's market valuation

Overall assessment

Annual Financial Ratios Фармсинтез

Price Earnings Ratio, P/E

Price Sales Ratio, P/S

Price To Book Ratio, P/B

Price Earnings To Growth Ratio, PEG

Operating Cash Flow Per Share

Free Cash Flow Per Share

Cash Per Share

Current Ratio

Quick Ratio

Cash Ratio

Days Of Sales Outstanding, DSO

Days Of Inventory Outstanding, DIO

Days Of Payables Outstanding, DPO

Operating Cycle

Cash Conversion Cycle

Gross Profit Margin

Operating Profit Margin

Pretax Profit Margin

Net Profit Margin

Effective Tax Rate

Return On Assets, ROA

Return On Equity, ROE

Return On Capital Employed, ROCE

Net Income Per Ebt

Ebt Per Ebit

Ebit Per Revenue

Debt Ratio

Debt Equity Ratio

Long Term Debt To Capitalization

Total Debt To Capitalization

Interest Coverage

Cash Flow To Debt Ratio

Company Equity Multiplier

Receivables Turnover

Payables Turnover

Inventory Turn Over

Fixed Asset Turnover

Asset Turnover

Operating Cash Flow Sales Ratio

Free Cash Flow Operating Cash Flow Ratio

Cash Flow Coverage Ratios

Short Term Coverage Ratios

Capital Expenditure Coverage Ratio

Dividend Paid And Capex Coverage Ratio

Price To Free Cash Flows Ratio, P/FCF

Price To Operating Cash Flows Ratio, P/OCF

Price Cash Flow Ratio, P/CF

Enterprise Value Multiple, EV

Price Fair Value, P/FV

Annual performance